Eli Lilly and Company (NYSE:LLY) Shares Unloaded Rep. David Taylor

Representative David Taylor (R-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on December 19th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on December 10th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 12/10/2025.
• Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 12/10/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 12/3/2025.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 12/3/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 11/12/2025.
• Purchased $1,001 – $15,000 in shares of RPM International (NYSE:RPM) on 11/11/2025.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/11/2025.
• Sold $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 11/3/2025.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 11/3/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 11/3/2025.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,076.38 on Tuesday. The firm’s 50 day simple moving average is $965.92 and its 200-day simple moving average is $833.56. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The firm has a market cap of $1.02 trillion, a PE ratio of 52.66, a price-to-earnings-growth ratio of 1.08 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 29.35%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. BMO Capital Markets set a $1,200.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, December 4th. Guggenheim restated a “buy” rating and issued a $1,163.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Morgan Stanley increased their price objective on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 15th. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,155.36.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LLY. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter worth approximately $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $27,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the last quarter. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at about $29,000. Finally, Steph & Co. boosted its holdings in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Updated clinical data released for Lilly’s breast cancer programs and the EMBER‑3 Phase 3 update for imlunestrant indicate meaningful progress on oncology/gynecologic pipelines, supporting long‑term revenue diversification beyond obesity. Read More.
• Positive Sentiment: Bank of America and other sell‑side activity remain constructive: BofA keeps a Buy on LLY (with a modest PT change) and Goldman raised a price target, signaling continued analyst conviction that obesity launches will drive earnings growth into 2027 and beyond. Read More.
• Positive Sentiment: Media and pundit attention (Jim Cramer) is highlighting a major catalyst for Lilly—continued commercialization and new indications for weight‑loss and other specialty drugs—which can attract retail flows and support multiple expansion. Read More.
• Positive Sentiment: Deal chatter: reports that Lilly met French officials and related market moves (Abivax) suggest Lilly is actively pursuing partnerships/licensing that could add pipeline value if deals materialize. Read More.
• Positive Sentiment: Technical/momentum signals note LLY trading near its 52‑week high, which can attract momentum traders and algos ahead of upcoming earnings and regulatory milestones. Read More.
• Neutral Sentiment: Market commentary pieces (Zacks, JP Morgan preview) are drawing attention to Lilly’s valuation, guidance and upcoming catalysts; useful for framing expectations but not immediate price movers. Read More. Read More.
• Neutral Sentiment: Analyst notes on biotech peers (CRISPR Therapeutics) mention a partnership with Lilly; this validates Lilly’s external R&D strategy but is secondary to Lilly’s own drug launches. Read More.
• Negative Sentiment: Regulatory setback for Lilly’s obesity franchise competitively: the FDA approved Novo Nordisk’s Wegovy oral pill—the first daily oral obesity drug—giving Novo a first‑mover advantage in the oral obesity market and adding near‑term competitive pressure on Lilly’s oral candidate (orforglipron). This is the primary headwind in today’s tape. Read More.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.